Travere Therapeutics, Inc.
NASDAQ:TVTX
17.57 (USD) • At close November 1, 2024
Overzicht | Financiële gegevens
Bedrijfsnaam | Travere Therapeutics, Inc. |
Symbool | TVTX |
Munteenheid | USD |
Prijs | 17.57 |
Beurswaarde | 1,343,955,655 |
Dividendpercentage | 0% |
52-weken bereik | 5.12 - 19.25 |
Industrie | Biotechnology |
Sector | Healthcare |
CEO | Dr. Eric M. Dube Ph.D. |
Website | https://www.travere.com |
An error occurred while fetching data.
Over Travere Therapeutics, Inc.
Travere Therapeutics, Inc., a biopharmaceutical company, focuses on the identification, development, commercialization, and delivering of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in gallbladders; Cholbam, a cholic acid capsule to treat pediatric
Vergelijkbare Aandelen
Financiële Gegevens
Cijfers zijn in miljoenen (USD)
Cijfers zijn in miljoenen (USD)